Showing 2511-2520 of 3315 results for "".
- Opthea Completes Manufacturing Milestone for Wet AMD Treatmenthttps://modernod.com/news/opthea-completes-manufacturing-milestone-for-wet-amd-treatment/2482447/Opthea announced the successful completion of its drug substance Process Performance Qualification (PPQ) campaign for sozinibercept, its lead candidate for treating wet age-related macular degeneration (AMD). The PPQ campaign involved the production of three consecutive commercial-scale
- Atsena Therapeutics Publishes 12-Month Safety and Efficacy Data from Phase 1/2 Trial of ATSN-101 in LCA1https://modernod.com/news/atsena-therapeutics-publishes-12-month-safety-and-efficacy-data-from-phase-12-trial-of-atsn-101-in-lca1/2482431/Atsena Therapeutics announced 12-month safety and efficacy results from its phase 1/2 clinical trial of ATSN-101, an investigational gene therapy for Leber congenital amaurosis (LCA1), a rare inherited retinal disease causing severe vision impairment or blindness from infancy. The findi
- Injectsense Completes First Successful Human Implant of Ultraminiature Intraocular Pressure Sensorhttps://modernod.com/news/injectsense-completes-first-successful-human-implant-of-ultraminiature-intraocular-pressure-sensor/2482413/Injectsense has announced the completion of the first human implant and subsequent wireless IOP measurements using its ultraminiature implantable sensor, which has received FDA breakthrough designation. The IOP-Connect system study is being conducted under the leadership
- Ocugen Receives Health Canada Approval to Initiate Phase 3 Clinical Trial for Retinitis Pigmentosahttps://modernod.com/news/ocugen-receives-health-canada-approval-to-initiate-phase-3-clinical-trial-for-retinitis-pigmentosa/2482410/Ocugen announced that Health Canada has provided a “No Objection Letter” to initiate the phase 3 Limelight clinical trial for OCU400 in Canada. OCU400 is a modifier gene therapy product candidate designed for the treatment of retinitis pigmentosa (RP). "Expand
- Study Targets Early Signs of Vision Loss in Diabetic Patientshttps://modernod.com/news/study-targets-early-signs-of-vision-loss-in-diabetic-patients/2482408/The University of Houston (UH) College of Optometry is embarking on a study, backed by a $3.3 million grant from the National Eye Institute, to investigate the progression of vision loss in patients with prediabetes and diabetes. The study, led by Associate Professor Wendy Harrison, aims to ident
- Visionix Unveils the VX 610 Automated Fundus Camerahttps://modernod.com/news/visionix-unveils-the-vx-610-automated-fundus-camera/2482407/Visionix USA announced the launch of the VX 610 non-mydriatic automated fundus camera. The VX 610 boasts a range of automated features, including auto alignment, auto focus, and auto capture. This level of automation not only streamlines the imaging process but also redu
- Inaugural Eyecelerator Innovation Award Presented to Regeneron Executiveshttps://modernod.com/news/inaugural-eyecelerator-innovation-award-presented-to-regeneron-executives/2482404/Leonard Schleifer, MD, PhD, and George Yancopoulos, MD, PhD, of Regeneron Pharmaceuticals were awarded the first Eyecelerator Innovation Award. "This year's Eyecelerator Innovation Award honors the remarkable physician-led, science-dr
- Opus Genetics Receives FDA Rare Pediatric Disease Designation for Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-receives-fda-rare-pediatric-disease-designation-for-gene-therapy-opgx-lca5/2482403/Opus Genetics announced that the FDA has granted rare pediatric disease (RPD) designation for its ocular gene therapy, OPGx-LCA5. This therapy is designed to treat patients with Leber congenital amaurosis (LCA) type 5, a rare inherited retinal disease caused by biallelic mutations in th
- Ocuvex Therapeutics Acquires Visiox Pharmaceuticalshttps://modernod.com/news/visiox-pharmaceuticals-merges-with-ocuvex-therapeutics/2482402/Early-stage ophthalmic biotech company Ocuvex Therapeutics announced an agreement to acquire Visiox Pharmaceuticals. Terms of the deal were not disclosed. Visiox's lead asset is Omlonti (omidenepag isopropyl ophthalmic solution 0.002%), an EP2 rece
- Atsena Therapeutics Secures FDA Rare Pediatric Disease Designation for XLRS Gene Therapyhttps://modernod.com/news/atsena-therapeutics-secures-fda-rare-pediatric-disease-designation-for-gene-therapy-targeting-x-linked-retinoschisis/2482398/The FDA has granted rare pediatric disease (RPD) designation for Atsena Therapeutics' gene therapy pruduct candidate ATSN-201, which is being examined to treat X-linked retinoschisis (XLRS). XLRS is a rare genetic disorder that leads to vision loss primarily in males.